<DOC>
	<DOC>NCT00830154</DOC>
	<brief_summary>A multicenter, randomized, 3 arm, placebo-controlled clinical trial to assess the efficacy, safety and tolerability of pagoclone for adults with stuttering.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering</brief_title>
	<detailed_description>A multicenter, randomized, 3-arm, placebo controlled, parallel group study with 24 weeks of double blind treatment followed by an 8 week double blind washout and then long-term open-label extension phase.</detailed_description>
	<mesh_term>Stuttering</mesh_term>
	<criteria>Male and females age 18 to 80 years presenting with a history of stuttering with onset prior to age 8 years old. Stuttering severity must be notable for &gt; 3 syllables stuttered on a reading and cenversational task at scereening and with at least 2% contributed individually from conversational and reading tasks. Patients with unstable hematological, autoimmune, endocrine, neurological, renal, hepatic, retinal, gastrointestinal, or cardiovascular disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stutter</keyword>
	<keyword>stuttering</keyword>
	<keyword>Adults with a history of stuttering</keyword>
</DOC>